Arrivent Biopharma, INC Form 4 insider transactions

ArriVent BioPharma's Chief Operating Officer, Robin LaChapelle, was granted 130,000 stock options with an exercise price of $22.67, vesting over four years.

ArriVent BioPharma's President of R&D, Stuart Lutzker, was granted 150,000 stock options with an exercise price of $22.67, vesting over four years.

ArriVent BioPharma's Chief Financial Officer, Winston Kung, was granted 140,000 stock options with an exercise price of $22.67, vesting over four years.

ArriVent BioPharma's President and CEO, Zhengbin Yao, was granted 550,000 stock options with an exercise price of $22.67, vesting over four years.

ArriVent BioPharma's General Counsel, James Paul Kastenmayer, received a grant of 130,000 stock options with a ten-year term and a four-year vesting schedule.

Hillhouse Investment Management and HHLR Advisors reported the sale of over 555,000 ArriVent BioPharma common shares for $23.37 each.

ArriVent BioPharma, Inc.'s Chief Operating Officer, Robin LaChapelle, reported the exercise of stock options to acquire 11,153 shares of common stock at an exercise price of $2.28 per share.

ArriVent BioPharma, Inc. (AVBP) Director Merdad Parsey was granted 15,502 non-qualified stock options with an exercise price of $24.89, as disclosed in a recent SEC Form 4 filing.

ArriVent BioPharma, Inc. Director Kristine Peterson was granted 15,502 non-qualified stock options with an exercise price of $24.89, exercisable from June 18, 2026.

ArriVent BioPharma, Inc. Director John Hohneker was granted 15,502 non-qualified stock options with an exercise price of $24.89, as disclosed in a recent SEC Form 4 filing.

ArriVent BioPharma, Inc. Director Chris Nolet was granted 15,502 non-qualified stock options with an exercise price of $24.89, as disclosed in a recent SEC Form 4 filing.

Director Merdad Parsey reports the acquisition of stock options in ArriVent BioPharma, Inc.

ArriVent BioPharma's CEO, Zhengbin Yao, reports the acquisition of stock options for 380,000 shares of common stock.

Stuart Lutzker, President of R&D at ArriVent BioPharma, acquired stock options for 120,000 shares of common stock on February 3, 2025.

Robin LaChapelle, Chief Operating Officer of ArriVent BioPharma, Inc., was granted stock options to purchase 120,000 shares of common stock on February 3, 2025.

Chief Financial Officer of ArriVent BioPharma, Winston Kung, reports the acquisition of stock options.

James Paul Kastenmayer, General Counsel of ArriVent BioPharma, acquired stock options for 102,000 shares on February 3, 2025.

Robin LaChapelle, Chief Operating Officer of ArriVent BioPharma, reports exercising stock options and changes in beneficial ownership of common stock.

Director John Hohneker of ArriVent BioPharma acquired stock options on May 16, 2024.

Kristine Peterson, a director at ArriVent BioPharma, acquired stock options exercisable for 28,587 shares of common stock on April 22, 2024.